Patent Number: 6,309,846

Title: Diagnosis and monitoring of colon cancer patients by measurement of NCA 50/90 in blood

Abstract: A method for aiding in the diagnosis of, and monitoring the progression or course of, colon cancer in a patient by measuring the amount of NCA 50/90 in a blood sample, e.g., serum sample, obtained from the patient. Measurement in a single sample of an amount of NCA 50/90 significantly higher than the mean amount of NCA 50/90 in the normal population is an indication of colon cancer in a symptomatic patient. The course of colon cancer can also be monitored by performing a series of specific immunoassays over time to determine changes in the level of NCA 50/90 in blood samples. Increases in blood NCA 50/90 levels over time are indicative of a deteriorating condition whereas decreasing levels of blood NCA 50/90 over time indicate an improving condition.

Inventors: Allard; William Jeffrey (Poughquag, NY), Yeung; Kwok K. (Prospect, CT)

Assignee: Bayer Corporation

International Classification: G01N 33/574 (20060101); G01N 033/574 (); G01N 033/48 (); G01N 033/53 (); G01N 033/543 ()

Expiration Date: 10/30/2018